The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global infant phototherapy devices market reached a value of US$ 82.6 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 105.9 Million by 2027, exhibiting a CAGR of 4.16% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Infant phototherapy devices are clinically proven and technologically advanced instruments that assist in treating neonatal jaundice. They also help cure hyperbilirubinemia by irradiating the infant with light that oxidizes the bilirubin in the blood. They prevent neurotoxic effects of high serum unconjugated bilirubin and reduce the need for exchange transfusion in neonates. They are either wrapped around and placed under or close to the baby and equipped with an hour meter to record bulb life and infant treatment time. As they are convenient and cost-effective, their application is increasing in hospitals and nursing homes across the globe.
There is a rise in the prevalence of jaundice, especially among premature babies, on account of enzyme deficiency, infections, liver problems, and abnormality in red blood cells. This, in confluence with significant developments in the healthcare infrastructure around the world, represents one of the key factors bolstering the growth of the market. Infant phototherapy devices rely on light absorbed by an infant’s skin to break down bilirubin into compounds. Apart from this, these devices cause the imbalance of thermal environment and water loss, electrolyte disturbance, bronze baby syndrome and circadian rhythm disorder. As a result, key players are developing new light devices and alternative agents to minimize the side effects of phototherapy, which is impelling the market growth. Furthermore, they are introducing proper eye protection that is easy to use, economical, removable, and appropriate for newborns. This, along with the innovation of effective, energy-efficient, and easy to move and clean devices, is positively influencing the utilization of infant phototherapy devices in rural hospitals with limited resources and inexperienced staff.
IMARC Group provides an analysis of the key trends in each sub-segment of the global infant phototherapy devices market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on light source, configuration and end user.
Breakup by Light Source:
Breakup by Configuration:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Atom Medical Corporation, AVI Healthcare Private Limited, Equalize Health, General Electric Company, Ibis Medical Equipment and Systems Pvt Ltd, Natus Medical Incorporated, Ningbo David Medical Device Company Limited, NOVOS Medical Systems, Weyer GmbH and Zhengzhou Dison Instrument and Meter Co. Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Light Source, Configuration, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Atom Medical Corporation, AVI Healthcare Private Limited, Equalize Health, General Electric Company, Ibis Medical Equipment and Systems Pvt Ltd, Natus Medical Incorporated, Ningbo David Medical Device Company Limited, NOVOS Medical Systems, Weyer GmbH and Zhengzhou Dison Instrument and Meter Co. Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at